>>Description of the research protocol "INCAGN 1876-201"

A Phase 1/2 study exploring the safety, tolerability, and efficacy of INCAGN01876 in combination with immune therapies in subjects with advanced or metastatic malignancies
Phase I study| Status : Ongoing and recruiting

Additional details

Indication (or studied pathology) : Toutes tumeurs
Brugmann identifier : INCAGN 1876-201
EudraCT identifier : 2016-004989-25


Involved department : Hemato-oncology
Principal investigator : Chapiro/Besse
Sponsor : Incyte
Contact : Clinical Research Unit

>This protocol was approved by the Bordet ethics committee.